Now, i know you're looking for something to downramp and be critical on (because that's all you know).
To be clear (because you obviously don't know), RC220 is not a new drug, whatsoever.
It is a new formulation, the pharmacodynamics of bisantrene will not change (There is an infinitesimally small chance of adverse reaction changes, the same reason generic brands must also undergo trials despite extremely minor adjustments).
This is like Paracetamol, woolworths generic brand is to RC110 thqt Panadol is to RC220.
They still do the same thing (pharmacodynamics), slightly different formulations for different brands.
RC220 not acting on the same pathways as RC110 isn't even a risk that registers on my radar.
RC220, from what we know is more likely to have less adverse reactions than the original formulation, but just like any formulation change it has to still be trialled and tested. I still rate that risk as pretty low.
- Forums
- ASX - By Stock
- RAC
- ASH2023 - Sheba 2.0
ASH2023 - Sheba 2.0, page-117
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.54 |
Change
-0.065(4.05%) |
Mkt cap ! $262.4M |
Open | High | Low | Value | Volume |
$1.62 | $1.62 | $1.51 | $261.3K | 168.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 30000 | $1.54 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.62 | 2000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 30000 | 1.540 |
1 | 121 | 1.535 |
1 | 700 | 1.520 |
1 | 3311 | 1.510 |
2 | 7320 | 1.505 |
Price($) | Vol. | No. |
---|---|---|
1.620 | 2000 | 1 |
1.650 | 7731 | 1 |
1.685 | 5000 | 1 |
1.690 | 6570 | 3 |
1.735 | 3313 | 1 |
Last trade - 15.59pm 09/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online